Bavencio

• 

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

By Sharon Kell|2019-10-03T07:45:31+00:003 Oct 2019|Drug treatments|

Results from the JAVELIN Renal 101 study to evaluate avelumab [...]

Read More

Comments Off on ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

• 

ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy

By Sharon Kell|2019-10-02T08:04:42+00:002 Oct 2019|Drug treatments|

Results from a post-hoc analysis of JAVELIN-Renal 101 in patients [...]

Read More

Comments Off on ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy

• 

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

By Sharon Kell|2019-09-30T10:40:26+00:0030 Sep 2019|Drug treatments|

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]

Read More

Comments Off on ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

• 

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

By Sharon Kell|2019-09-20T17:17:54+00:0020 Sep 2019|Drug treatments|

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]

Read More

Comments Off on European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

• 

Avelumab plus axitinib combination available via EAMS

By Sharon Kell|2019-07-16T15:01:56+00:0016 Jul 2019|Drug treatments|

It has just been announced that the avelumab plus axitinib [...]

Read More

Comments Off on Avelumab plus axitinib combination available via EAMS

• 

ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

By Sharon Kell|2019-06-04T12:52:09+00:004 Jun 2019|Drug treatments, Uncategorized|

Results from the biomarker analysis from the JAVALIN Renal 101 [...]

Read More

Comments Off on ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

• 

Avelumab plus axitinib granted FDA approval for advanced kidney cancer

By Sharon Kell|2019-05-16T08:04:27+00:0016 May 2019|Drug treatments|

The Food and Drug Administration (FDA) in the United States [...]

Read More

Comments Off on Avelumab plus axitinib granted FDA approval for advanced kidney cancer

• 

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

By Sharon Kell|2019-02-27T11:11:31+00:0027 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

• 

Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

By Sharon Kell|2018-11-28T14:47:57+00:0028 Nov 2018|Drug treatments|

The following article from Practice Update discusses the JAVELIN Renal [...]

Read More

Comments Off on Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

• 

Promising avelumab plus axitinib data in renal cell carcinoma

By Sharon Kell|2018-11-23T09:41:05+00:0023 Nov 2018|Drug treatments|

The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr [...]

Read More

Comments Off on Promising avelumab plus axitinib data in renal cell carcinoma